US Corporate Distress Financial Stress SEC Filings — June 04, 2026

04-06-2026

NextTrip, Inc. (NTRP) borrowed $200,000 on May 29, 2026 from The Donald P. Monaco Insurance Trust, a related party (director Donald P. Monaco is trustee), as part of a series of short-term unsecured loans. The total principal balance of these Monaco Loans is now $500,000, accruing interest at 7.5% simple interest per annum, with a maturity date of June 30, 2026. The loans were approved by the Board of Directors and Audit Committee, but the short-term nature and reliance on insider funding may signal liquidity constraints.

• · The Monaco Loans commenced on March 25, 2026, and the $200,000 borrowed on May 29 is the latest in that series.
• · The loans are unsecured and mature on June 30, 2026, indicating very short-term financing.
• · The loans were approved by both the Board of Directors and the Audit Committee, suggesting governance oversight of the related-party transaction.

04-06-2026

Atkore Inc. entered into a settlement agreement on June 3, 2026, with the End User Plaintiffs in the In re PVC Pipe Antitrust Litigation, agreeing to pay $50 million to resolve all claims. The settlement is subject to court approval and is expected to be funded from available cash, with no material adverse effect on liquidity or leverage metrics. The company does not admit fault and believes the settlement reduces legal uncertainty, but there is no assurance of final court approval.

• · The settlement will be reflected as a non-operating expense in the quarter ending June 26, 2026.
• · The settlement payment is due on or about 21 days after preliminary court approval.
• · The settlement covers all claims including potential parens patriae claims.
• · The company previously entered into settlement agreements with two of the three putative classes on April 28, 2026.
• · If the settlement is not approved, the company plans to vigorously defend itself.

04-06-2026

Smith-Midland Corporation received a notice from Nasdaq on May 29, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, violating Nasdaq Listing Rule 5250(c)(1). The notice has no immediate effect on the listing of its common stock on the Nasdaq Capital Market, and the company is working to file the Form 10-Q as promptly as possible. If unable to file by July 28, 2026, the company intends to submit a plan to regain compliance.

• · The company has until July 28, 2026, to file the Form 10-Q or submit a compliance plan to Nasdaq.
• · A press release regarding the late filing was issued on June 3, 2026, and attached as Exhibit 99.1 to the 8-K.

04-06-2026

Marsh & McLennan Companies, Inc. entered into a $4.25 billion amended and restated five-year credit agreement dated June 2, 2026, replacing its prior $3.5 billion credit agreement from October 2023. The facility is available to the company, Calm Treasury Holdings Limited, MMC Securities LLC, and designated subsidiaries, with Citibank as administrative agent and a syndicate of major banks as joint lead arrangers. The agreement includes customary representations, covenants, events of default, and a guaranty from the company, reflecting an increase in total commitments of $750 million (21.4%) from the prior facility.

• · The agreement is dated June 2, 2026, and was filed as an 8-K on June 4, 2026.
• · Borrowers include the company, Calm Treasury Holdings Limited (formerly MMC Treasury Holdings (UK) Limited), MMC Securities LLC, and any designated subsidiaries.
• · The facility is a five-year revolving credit agreement with a termination date extending the maturity from the prior agreement.
• · The agreement includes a guaranty from Marsh & McLennan Companies, Inc. for obligations of its subsidiaries.
• · The syndication agents include Bank of America, Deutsche Bank, HSBC, JPMorgan Chase, and Wells Fargo.
• · Documentation agents include Barclays, Morgan Stanley, MUFG, PNC, Toronto-Dominion, Bank of Nova Scotia, and Royal Bank of Canada.
• · The agreement contains standard financial covenants, negative pledge, and events of default provisions.
• · The facility can be used for general corporate purposes and includes provisions for letters of credit.

04-06-2026

Syndax Pharmaceuticals announced a private placement of $250.0 million in 2.25% Convertible Senior Notes due 2031, expected to close on June 10, 2026, with net proceeds of approximately $243 million for general corporate purposes. The notes carry a 2.25% interest rate, mature on June 15, 2031, and have an initial conversion price of $24.76 per share, representing a 35% premium over the stock's last reported sale price on June 3, 2026. The company is a commercial-stage biopharmaceutical firm with FDA-approved products Revuforj and Niktimvo, but the filing does not disclose any negative or flat performance metrics.

• · Notes are senior unsecured obligations with interest payable semiannually on June 15 and December 15, starting December 15, 2026.
• · Noteholders may convert at any time prior to March 15, 2031 only upon certain circumstances; after that date, conversion is allowed at any time until the second scheduled trading day before maturity.
• · Upon conversion, Syndax may pay cash, shares of common stock, or a combination, at its election.
• · Syndax cannot redeem the notes before June 20, 2029; after that, redemption is allowed if stock price is at least 130% of conversion price for 20 trading days in a 30-day period.
• · In a fundamental change, noteholders can require Syndax to repurchase notes at 100% of principal plus accrued interest.
• · The notes and any conversion shares are not registered under the Securities Act and cannot be offered or sold in the U.S. without registration or an exemption.

04-06-2026

CONMED Corporation entered into privately negotiated purchase agreements on June 3, 2026 to repurchase approximately $645.2 million aggregate principal amount of its 2.25% Convertible Senior Notes due 2027 for approximately $637.2 million in cash. The transaction is expected to close on June 15, 2026, subject to customary closing conditions. This debt repurchase reduces the company's outstanding convertible debt but also consumes significant cash reserves.

• · The repurchase price of $637.2M represents a discount of approximately $8.0M (1.24%) from the principal amount of $645.2M.
• · The Notes carry a 2.25% coupon and mature in 2027.
• · The purchase agreements were entered into on June 3, 2026, and the filing was made on June 4, 2026.

04-06-2026

Bio Green Med Solution, Inc. (BGMS) announced a business combination agreement to acquire Future NRG Sdn. Bhd. in an all-stock share exchange, creating a next-generation environmental platform combining fire safety and medical waste treatment. The transaction is expected to close in Q4 2026, subject to shareholder and regulatory approvals. While the deal targets a large underserved market with proven green technology, it faces execution risks including shareholder approval, SEC registration, and customary closing conditions.

• · Future NRG operates a medical waste plant with 10 metric tons per day capacity using ozone gas (O₃) for disinfection, eliminating carbon emissions from incineration.
• · The combined company will be led by current BGMS CEO Datuk Dr. Doris Wong; Conner Kiu steps down as director but remains CFO.
• · Pun Kah Weng will join the board as Future NRG's appointee.
• · The transaction is subject to approval by both companies' shareholders, SEC effectiveness of Form S-4, and customary closing conditions.
• · BGMS common stock has a par value of $0.001 per share.

04-06-2026

Applied Aerospace & Defense, Inc. filed an 8-K on June 4, 2026, announcing the adoption of a Second Amended and Restated Certificate of Incorporation. The amendment includes a 1:1 conversion of Class A and Class B common stock into a single class of Common Stock, followed by a massive 872,901.03-for-1 stock split, and establishes a classified board with three classes of directors. The changes are part of preparations for an initial public offering (IPO).

• · The company was originally incorporated as GB Eagle Topco, Inc. on October 7, 2022.
• · The authorized capital stock consists of 50,000,000 shares of Preferred Stock and 1,000,000,000 shares of Common Stock, each with $0.01 par value.
• · No fractional shares will be issued; fractional shares will be rounded up to the nearest whole share.
• · The Board is authorized to issue Preferred Stock in series with varying rights, which may be superior to Common Stock.
• · The Board is classified into three classes (Class I, II, III) with staggered three-year terms.
• · Before the Trigger Date, directors can be removed with or without cause by a majority vote; after the Trigger Date, removal requires cause and a 66 2/3% vote.
• · The Stockholders Agreement is referenced as governing certain director election and vacancy provisions.

04-06-2026

Minerva Neurosciences, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation on June 4, 2026. The amendment limits the monetary liability of directors and officers for breach of fiduciary duty to the fullest extent permitted under Delaware law, and reserves Article NINTH. The amendment was approved by the Board and stockholders.

• · The original certificate of incorporation was filed on April 23, 2007 under the name Cyrenaic Pharmaceuticals, Inc.
• · The amendment to Article EIGHTH limits director and officer liability for monetary damages for breach of fiduciary duty, with 'officer' defined per Section 102(b)(7) of the DGCL.
• · Article NINTH is now reserved.
• · The amendment was adopted in accordance with Section 242 of the DGCL.

04-06-2026

Highwoods Realty Limited Partnership and Highwoods Properties, Inc. entered into a Sixth Amendment to their Sixth Amended and Restated Credit Agreement on June 3, 2026, with Bank of America as Administrative Agent. The amendment modifies certain provisions, reallocates Term A-2 Loans among lenders, and requires compliance with financial covenants as of March 31, 2026, while confirming no Default exists and no Material Adverse Effect has occurred since December 31, 2025.

• · The amendment reallocates Outstanding Term A-2 Loans among Term A-2 Lenders to reflect each lender's Applicable Percentage.
• · Conditions precedent include delivery of legal opinions from Poyner Spruill LLP, Jeffrey D. Miller, and Haynes and Boone, LLP.
• · The Borrowers certified compliance with financial covenants as of March 31, 2026, and that no Material Adverse Effect has occurred since December 31, 2025.
• · The amendment requires delivery of Beneficial Ownership Certification for any Loan Party qualifying as a 'legal entity customer' under the Beneficial Ownership Regulation.
• · The Credit Agreement is governed by New York law.

04-06-2026

Z Squared Inc. (Nasdaq: ZSQR) announced a $50 million committed equity forward purchase agreement with LucentHash / Data Part Capital to fund its Phase 1 AI infrastructure buildout, targeting 100 megawatts of AI-ready capacity across multiple U.S. sites. The company has signed a binding letter of intent to acquire Skycore Digital, which owns three North Carolina sites with up to 42 megawatts of total potential capacity (18 megawatts currently available). However, the company currently generates no revenue from AI infrastructure operations and remains dependent on volatile cryptocurrency mining for existing revenue, with significant execution risks around acquisitions, conversions, and customer contracting.

• · The company listed on the Nasdaq Global Market in April 2026.
• · The company currently has virtually no debt on its balance sheet.
• · LucentHash / Data Part Capital is contractually prohibited from short-selling or hedging ZSQR common stock.
• · The company is actively evaluating additional acquisition opportunities beyond Skycore Digital.
• · The company's existing revenue is dependent on cryptocurrency mining (Dogecoin) and is subject to volatility in cryptocurrency markets, mining economics, and network difficulty.

04-06-2026

On June 1, 2026, Accuray Incorporated fully repaid the remaining $18.0M aggregate principal of its 3.75% Convertible Senior Notes due 2026, plus $337,500 in accrued interest, satisfying and discharging the related Indenture. This eliminates the company's remaining obligations under the note agreement, reducing debt and interest expense going forward.

• · Notes were originally issued on May 13, 2021, with a coupon rate of 3.75% and maturity date of June 1, 2026.
• · The Indenture was satisfied and discharged except for provisions that survive by their terms.
• · The trustee acknowledged the satisfaction and discharge, releasing the Company from remaining obligations under the Indenture.

04-06-2026

Resideo Technologies, Inc. entered into a Second Amendment and Restatement Agreement on June 4, 2026, to amend its existing credit facility, repay revolving loans, and terminate revolving commitments. The amendment also facilitates the planned spin-off of its ADI global distribution business (expected around August 3, 2026), which will involve a distribution of at least $900 million to Resideo and the release of ADI entities from guarantees and collateral. The company also plans to merge the borrower entity into Resideo Funding II, LLC.

• · The amendment includes both Refinancing Amendments (repaying revolving loans, terminating commitments) and Non-Refinancing Amendments (to permit the ADI spin-off).
• · The ADI Spin-Off Transaction is expected to be completed through a pro rata distribution of all outstanding shares of ADI Global Distribution Inc. to Resideo stockholders.
• · The ADI Spin-Off Entities will be released from guarantees and collateral upon effectiveness of the spin-off, subject to reinstatement if the transaction does not occur.
• · The borrower (Resideo Funding Inc.) plans to merge into Resideo Funding II, LLC, which will become the sole borrower under the amended credit agreement.
• · The amendment also modifies the definition of 'Paid in Full' in the collateral agreement to exclude certain obligations not yet due.

04-06-2026

Cheetah Net Supply Chain Service Inc. (CTNT) announced the resignation of CFO Cindy Tang, effective May 29, 2026, with no disagreement cited. Chairman and CEO Huan Liu has assumed the role of interim CFO. The company entered into a Separation Agreement with Tang on June 4, 2026, providing a $50,000 stock incentive payment (settled in cash) in exchange for confidentiality, non-disparagement, and release of claims. The departure creates a leadership gap, though the board plans to search for a permanent replacement.

• · Resignation was effective May 29, 2026, and the Separation Agreement was signed June 4, 2026.
• · Tang received her final paycheck on May 29, 2026.
• · The board intends to conduct a search for internal and external candidates to fill the CFO vacancy.
• · No disagreement was cited as the reason for resignation.

04-06-2026

Sanara MedTech Inc. terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective June 2, 2026, as part of a strategic shift to focus on soft tissue repair and bone fusion products for the surgical market. The termination was mutual, with no fee or penalty paid, though certain covenants like indemnification and confidentiality remain in effect. The agreement's termination removes a material relationship with Chairman Ronald T. Nixon's firm, which beneficially owns over 5% of the company's stock.

• · The Services Agreement was originally entered into on March 20, 2023, effective March 1, 2023.
• · Catalyst and its affiliates collectively beneficially own more than 5% of the Company’s outstanding common stock.
• · The Mutual Termination Agreement was signed on June 2, 2026, and terminated the Services Agreement immediately.
• · No fee or penalty was paid in connection with the termination.

04-06-2026

Borealis Foods Inc. issued a $3,000,000 convertible promissory note to OXUS CAPITAL PTE LTD on May 29, 2026, with a maturity date of August 29, 2026, and 10% annual interest. The proceeds are restricted to paying accounts payable, fees, and working capital, and cannot be used to repay existing debt. The note is convertible into common stock at the holder's option upon maturity, subject to a 49.9% ownership blocker and anti-dilution adjustments, but conversion requires shareholder approval under Nasdaq rules.

• · The note matures on the earlier of August 29, 2026 or upon acceleration after an Event of Default.
• · Events of Default include failure to pay, breach of covenants, misrepresentations, default on other debt ≥$500,000, judgments ≥$500,000, and bankruptcy/insolvency proceedings.
• · Voluntary prepayment is allowed without premium or penalty, applied first to expenses, then interest, then principal.
• · Conversion requires the Company to obtain all Required Approvals (including shareholder approval under Nasdaq rules) before the Conversion Date.
• · The note is subject to a four-month-and-a-day resale restriction under Canadian securities laws.
• · The note has not been registered under the Securities Act of 1933 and is issued under Regulation S and Canadian exemptions.

04-06-2026

Allied Energy, Inc. (AGGI) filed Articles of Amendment to change its name to BILI Social International, Inc. and effect a 1-for-500 reverse stock split, effective upon FINRA announcement. The amendments were adopted by the board without shareholder approval, and no fractional shares will be issued; holders will receive cash in lieu of fractional interests.

• · The reverse split does not change the authorized number of shares or par value ($0.001 per share).
• · Shareholder approval was not required under Section 607.10025 of the Florida Business Corporation Act.
• · The effective date will be announced by FINRA for marketplace implementation.
• · New principal office address: 625 Broad Street 2nd Floor, Suite 240, Newark, NJ 07102.
• · New registered agent and registered office address in Florida were not changed (left blank).

04-06-2026

On May 29, 2026, DNA X, Inc. (formerly Sonim Technologies Inc., trading as SONM) terminated its ChEF Purchase Agreement and related Registration Rights Agreement with Chardan Capital Markets LLC, effective May 28, 2026. The agreement, entered into on September 29, 2025, had provided for up to $500 million in common stock purchases. The termination eliminates a potential source of equity financing, which may impact the company's liquidity and capital-raising flexibility.

• · The termination was effective as of 5:00 p.m., New York City time, on May 28, 2026.
• · The ChEF Agreement was originally entered into on September 29, 2025.
• · The company's common stock trades under the symbol SONM on The Nasdaq Stock Market LLC.

04-06-2026

Nu Ride Inc. (OTC: NRDE) announced an agreement to acquire a majority stake in Affinity Advisory Network, an insurance distribution and wealth advisory platform, for approximately $9.6 million. The transaction includes $6.72 million in cash, 80,000 shares of Class A common stock, and up to $1.312 million in earnout payments, with Affinity's founder retaining a 15% ownership interest. While Affinity generated over $3.5 million in revenue for the 12 months ended March 31, 2026, the acquisition is subject to customary closing conditions and expected to close in Q3 2026, with no guarantee of realizing anticipated benefits.

• · Affinity was founded in 2013 and is headquartered in Ohio.
• · The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.
• · Robert Hall will continue to lead Affinity following the closing.
• · Nu Ride believes there will be multiple organic and inorganic growth opportunities over time.

04-06-2026

Avalon GloboCare Corp. issued a $250,000 promissory note with an original issue discount of $50,000, resulting in net proceeds of $200,000 (after $5,000 legal fee deduction). The note carries an 18.75% one-time interest charge ($46,875) and requires four amortization payments starting September 1, 2026, with the final balance due at maturity on December 1, 2026. The filing also includes provisions for mandatory repayment from proceeds of future financings or asset sales, and events of default include failure to maintain Nasdaq listing.

• · The note is non-convertible and cannot be prepaid except as explicitly set forth (though full prepayment is allowed without penalty).
• · The Borrower must notify Holder within one business day of receiving proceeds from equity/debt issuance or asset sales; Holder can then require up to 25% of such proceeds (net of certain fees) to repay the note.
• · Events of default include failure to maintain listing of common stock on Nasdaq Capital Market, bankruptcy, liquidation, cessation of operations, and breach of covenants.
• · The note is governed by Delaware law and any disputes must be brought in federal courts in Delaware.
• · Transfers of the note require the transferee to be an 'accredited investor' under SEC Rule 501(a).

04-06-2026

Biomerica Inc. entered into a Securities Purchase Agreement on May 29, 2026 to sell its 78,750 shares (approximately 6% stake) in Diagnosis S.A., a Polish medical products company, for an aggregate purchase price of $500,000 (approximately $6.3492 per share). The transaction closed on the same date, with the purchase price delivered via a secured promissory note that is forgivable upon share transfer. Biomerica also disclosed it received a $52,000 dividend from Diagnosis S.A. in 2026, which was considered by its Board in approving the sale price.

• · The purchase price per share was $6.3492, rounded for convenience, with the aggregate $500,000 controlling.
• · The shares are not registered under the Securities Act of 1933 and may not be transferred except under registration or an applicable exemption.
• · Biomerica represented that the shares are free and clear of all encumbrances and that no additional governmental or third-party consents are required beyond Polish law requirements.
• · If shareholder register evidence is not provided within 15 business days after closing, Biomerica must refund the applicable purchase price to the affected buyer.
• · The agreement is governed by Delaware law.

04-06-2026

Lixte Biotechnology Holdings, Inc. closed a registered direct offering on June 4, 2026, raising approximately $16.6 million in gross proceeds through the sale of 2,625,362 shares of common stock and pre-funded warrants priced at $6.31 per share at the market under Nasdaq rules. The company intends to use the net proceeds for general corporate purposes and working capital. No period-over-period financial comparisons are available in this filing.

• · The offering was made under an effective shelf registration statement on Form S-3 (No. 333-278874) filed with the SEC and declared effective on May 2, 2024.
• · The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full.
• · The company's lead compound LB-100 is a first-in-class PP2A inhibitor being studied in clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
• · Lixte also has a wholly owned subsidiary, Liora Technologies Europe Ltd., developing the LiGHT System for proton therapy.

04-06-2026

Datavault AI Inc. (DVLT) announced a non-binding term sheet for a potential $2.0 billion structured financing transaction, under which it may issue shares at $1.55–$2.00 per share to an institutional fund and a UK-based platform in exchange for preferred units in a fixed income vehicle. The counterparty also granted an exclusive global mandate for its digital asset tokenization projects through Datavault AI's platform. However, the transaction is non-binding, subject to definitive agreements, due diligence, shareholder approval, and regulatory clearances, and the company has a binding obligation to pay a non-refundable $25.0 million structuring fee by June 4, 2026, with no guarantee of completion.

• · The counterparty includes an institutional investment fund and a UK-based regulated structured institutional investment platform operating across technology, mining, and real assets.
• · The transaction is structured across four successive tranches of up to $500 million each, with the initial tranche targeting completion by Q3 2026.
• · Upon closing of each tranche, the counterparty may nominate one additional director (replacing a seated director); after the final tranche, the counterparty would gain voting power to elect a majority of the board.
• · The company has a binding obligation to pay $25.0 million non-refundable structuring fee by June 4, 2026, funded from sale of bitcoin and receivables.
• · The proposed transaction is subject to shareholder approval, regulatory approvals (including antitrust and CFIUS review), a charter amendment to increase authorized shares, and a fairness opinion.
• · The company reported $800 million in tokenization contracts signed in 2026 and a $60 million registered direct offering closed, bringing working capital to approximately $140 million.
• · The CLARITY Act cleared the Senate Banking Committee on May 14, 2026, and is awaiting a Senate floor vote.
• · The company's SanQtum network is live in New York and Philadelphia, with a target of 48,000 GPUs across 100 U.S. cities by year-end 2026.
• · The company holds more than 100 issued U.S. patents, including four jointly owned patents (Nos. 10,607,291; 11,410,236; 11,861,707; 12,198,193) related to NYIAX.

04-06-2026

B&G Foods, Inc. (NYSE: BGS) priced a $475.0 million offering of 11.00% senior notes due 2031 at 97.67% of par, expected to close on June 10, 2026. Net proceeds of approximately $456.3 million, together with borrowings under its revolving credit facility and cash on hand, will be used to redeem all $509.3 million of its outstanding 5.25% senior notes due 2027 and pay related fees and expenses. The new notes carry a significantly higher coupon (11.00% vs. 5.25%), reflecting increased leverage and refinancing risk, though the transaction extends the maturity profile from 2027 to 2031.

• · The new notes are being issued at 97.67% of par, indicating a discount to face value.
• · The offering is exempt from registration under the Securities Act of 1933, relying on Rule 144A and Regulation S.
• · The notes will be guaranteed on a senior unsecured basis by certain domestic subsidiaries of B&G Foods.
• · The redemption of the 5.25% notes due 2027 will be funded with net proceeds, borrowings under the revolving credit facility, and cash on hand.
• · The press release does not constitute a redemption notice for the 2027 notes.

04-06-2026

Abpro Holdings, Inc. received final notification from the Nasdaq Listing and Hearing Review Council on May 28, 2026, reaffirming the delisting of its securities due to failure to meet the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by the February 16, 2026 deadline. The company's common stock (ABP) and warrants (ABPWW) were already delisted from Nasdaq and have been trading on the OTC Pink Market since February 23, 2026. The company cautions that trading on the OTC Pink Market may involve limited information, reduced transparency, and lower liquidity.

• · The company had been required to demonstrate compliance with the minimum equity standard under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026, per the Panel's November 10, 2025 decision.
• · Trading on the OTC Pink Market began on February 23, 2026, under symbols ABP (common stock) and ABPWW (warrants).
• · Nasdaq is expected to file a Form 25 with the SEC to formally delist and deregister the securities under Section 12(b) of the Exchange Act.
• · The company provides no assurances that any broker-dealer will make a market in its common stock or public warrants or that trading levels, liquidity, or quotation prices will be maintained.

04-06-2026

NRx Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 5,714,286 shares of common stock at $3.50 per share, for gross proceeds of approximately $20.0 million (or $23.0 million if the over-allotment option is fully exercised). The company intends to use the net proceeds for working capital and general corporate purposes, while noting it is a clinical-stage biopharmaceutical company with no approved products and ongoing development programs for NRX-100 and NRX-101, which carry inherent regulatory and commercialization risks.

• · The offering is priced at $3.50 per share, which is at a discount to recent trading levels but not specified in the filing.
• · BTIG, LLC is lead bookrunning manager; Lucid Capital Markets, LLC is joint bookrunning manager.
• · The offering is conducted under an effective shelf registration statement on Form S-3 (File No. 333-288205) declared effective December 22, 2025.
• · The company has no approved products and is developing NMDA platform drugs for suicidal depression, chronic pain, and PTSD.
• · NRX-100 has Fast Track Designation for suicidal ideation in depression; NRX-101 has Breakthrough Therapy Designation for suicidal bipolar depression.
• · The company has filed an Abbreviated New Drug Application (ANDA) and initiated an NDA filing for NRX-100.

04-06-2026

Cycurion, Inc. filed a Certificate of Designation for a new Series H Convertible Preferred Stock, authorizing up to 10,000 shares of preferred stock for issuance in exchange for other securities or property. The company currently has 6,781,367 shares of preferred stock issued and outstanding out of 20,000,000 authorized shares. The filing establishes conversion rights, redemption terms, and other preferences for the new series, which may dilute existing common shareholders upon conversion.

• · The Series H Convertible Preferred Stock has a par value of $0.0001 per share.
• · The Certificate of Designation includes a Beneficial Ownership Limitation provision (Section 6(d)) that restricts conversion to prevent the holder from exceeding 4.99% beneficial ownership of common stock.
• · The filing references an 'Exchange Agreement' under which the Series H shares will be issued in exchange for other securities of Cycurion.
• · The preferred stock carries conversion rights into common stock at a defined conversion price, with provisions for anti-dilution adjustments and alternate consideration in case of fundamental transactions.
• · Any converted or redeemed shares of Series H will revert to authorized but unissued preferred stock and will no longer be designated as Series H.

04-06-2026

MSP Recovery, LLC received a one-time limited advance of $61,228.73 from VRM MSP Recovery Partners LLC (managed by Virage Capital Management LP) to support accounts payable. The advance must be immediately reimbursed from proceeds of any future loan or financial transaction (excluding short-term financing from Hazel Partners Holdings, LLC), and MSP Recovery must agree to appoint Nader Tavakoli as Chief Restructuring Officer. The agreement references multiple prior consents and advances dating back to September 2025, indicating ongoing liquidity support from Virage.

• · The advance is subject to immediate reimbursement from proceeds of any loan or financial transaction (excluding Hazel Partners short-term financing), including debtor-in-possession financing if MSP Recovery files for Chapter 11.
• · MSP Recovery must agree to appoint Nader Tavakoli as Chief Restructuring Officer before using the advance.
• · The agreement references seven prior consents for use of Recovery Proceeds and five prior advances from Virage dating back to March 2026, indicating a pattern of repeated liquidity support.
• · The advance is explicitly a one-time arrangement with no obligation for further advances.

04-06-2026

Veea Inc. disclosed that it is no longer in compliance with Nasdaq's majority independent director, audit committee, and compensation committee requirements following the unexpected passing of board member Douglas Maine on June 1, 2026. The company received a cure period from Nasdaq until the earlier of its next Annual Meeting of Shareholders or May 31, 2027 (with a potential earlier deadline of November 27, 2026). While the company intends to regain compliance, there is no assurance it will succeed, though the listing is not immediately affected.

• · The company's common stock (VEEA) and warrants (VEEAW) continue to trade on the Nasdaq Capital Market with no immediate effect on listing.
• · The cure period extends until the earlier of the next Annual Meeting of Shareholders or May 31, 2027, but if the next Annual Meeting is held before November 27, 2026, compliance must be achieved by November 27, 2026.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.

04-06-2026

Aeva Technologies, Inc. announced a proposed follow-on public offering of $100,000,000 of its common stock on June 3, 2026, with an underwriter option to purchase an additional $15,000,000. The offering is subject to market conditions, and net proceeds will be used for general corporate purposes, including AI infrastructure and Co-Packaged Optics initiatives. Morgan Stanley, Goldman Sachs & Co. LLC, and Oppenheimer & Co. are acting as book-running managers.

• · The offering is being made pursuant to an automatically effective shelf registration statement on Form S-3 filed with the SEC on June 3, 2026.
• · No assurance is given as to whether or when the offering may be completed, or as to the actual size or terms.
• · The underwriters have a 30-day option to purchase up to an additional $15,000,000 of shares.
• · The preliminary prospectus supplement will be filed with the SEC, and copies can be obtained from Morgan Stanley, Goldman Sachs, and Oppenheimer.

04-06-2026

Hilton Grand Vacations Inc. (HGV) entered into an underwriting agreement on June 2, 2026, with affiliates of Apollo Global Management as selling stockholders and Wells Fargo Securities as representative of the underwriters, for the sale of 5,000,000 shares of common stock (plus an over-allotment option of up to 750,000 shares). The company will repurchase 750,000 shares from the underwriters as part of the offering, with no underwriting fees on those shares. HGV will not receive any proceeds from the sale of shares by the selling stockholders.

• · The offering is made under a shelf registration statement on Form S-3 (File No. 333-289538) filed on August 12, 2025.
• · The company will not receive any proceeds from the sale of shares by the selling stockholders.
• · The underwriters will not receive any underwriting fees for the shares repurchased by the company.
• · The share repurchase is authorized by a board-approved share repurchase plan.
• · The underwriting agreement includes customary representations, warranties, conditions to closing, indemnification, and termination rights.

04-06-2026

IMUNON announced a $10 million cash financing consisting of $2.5 million from preferred stock and $7.72 million from secured promissory notes (8% and 5% interest, 18-month maturity). The funds will support the Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer. Updated Phase 2 data showed median overall survival improved from 11.1 to 14.7 months, and PARP inhibitor combination yielded a 24.2-month OS benefit versus standard of care.

• · The financing includes no warrants, reducing dilution for existing shareholders.
• · Interest on promissory notes will be partially offset by interest earned via bank deposit.
• · Phase 3 OVATION 3 will enroll 500 patients randomized 1:1, with two interim analyses for potential early registration.
• · Phase 2 OVATION 2 was not powered for statistical significance.
• · Epithelial ovarian cancer has a 75% recurrence rate for stage III/IV and five-year survival rates of 41% (stage III) and 20% (stage IV).
• · IMUNON has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

04-06-2026

VisionWave Holdings, Inc. entered into a Securities Exchange Agreement to acquire a 52% controlling stake in Foresight Autonomous Holdings Ltd. in two stages, with total consideration of $17.5 million in VisionWave common stock plus up to $3 million in management equity grants. The acquisition aims to establish Foresight as the core operating platform for VisionWave's RF-focused perception systems and defense/autonomous technology initiatives. However, the agreement includes a value protection mechanism that could require VisionWave to issue additional make-whole shares if Foresight's proceeds from selling VisionWave stock fall below a protected amount, and the Stage 2 closing is conditional on an uncertain milestone.

• · Stage 1 closing expected within 45–60 days of the effective date (June 2, 2026).
• · Stage 2 closing is conditional upon commencement of a binding pilot project utilizing the integrated Perception Platform in commercial, defense, or security sector.
• · Value protection mechanism: if Foresight sells all VisionWave shares and realizes aggregate gross proceeds below the Protected Amount ($10,062,500 for Stage 1; $1,312,500 for Stage 2) within a two-year Protection Period, VisionWave must issue additional Make-Whole Shares.
• · Failure to issue Make-Whole Shares on time triggers liquidated damages of 1.5% of the shortfall amount per 30-day period.
• · Leak-out agreement limits Foresight's daily sales of VisionWave common stock to 5% of actual daily trading volume for 36 months.
• · Foresight must allocate no less than 50% of proceeds from sales of VisionWave common stock to the Perception Platform.
• · Registration statement (Form S-1/S-3) must be filed within 45 days of each closing.
• · VisionWave has audit rights to inspect Foresight's trading records to verify compliance with leak-out and allocation covenants.
• · The agreement includes mutual representations, warranties, covenants, indemnification, and termination provisions customary for such transactions.

04-06-2026

MIRA Pharmaceuticals secured worldwide exclusive rights to MIRA-55 and SKNY-1 via an amended license agreement with MIRALOGX LLC, consolidating its IP portfolio and enabling unified global development and commercialization. The agreement does not materially modify previously disclosed core economic terms. The company now controls global rights across its entire pipeline (Ketamir-2, MIRA-55, SKNY-1) as it advances Ketamir-2 into Phase 2a and moves MIRA-55 and SKNY-1 toward IND filings.

• · MIRA-55 is a next-generation cannabinoid analog targeting CB1 and CB2 pathways with minimized CB1-related psychoactivity; in preclinical models, it demonstrated analgesic activity comparable to injected morphine.
• · The DEA confirmed MIRA-55 is not classified as a controlled substance.
• · SKNY-1 is designed to modulate CB1, CB2, and MAO-B pathways; in preclinical studies, oral administration showed dose-dependent weight reduction and lipid normalization without significant reduction in whole-body density.
• · The agreement provides worldwide sublicensing rights and enhanced IP enforcement rights.
• · MIRA-55 is being developed for chronic inflammatory pain; SKNY-1 for obesity and addiction-related disorders.
• · The company is a clinical-stage pharmaceutical company focused on neurologic, neuropsychiatric, inflammatory, and metabolic disorders.

04-06-2026

Health Catalyst announced the divestiture of its Vitalware mid-revenue cycle business to Med-Metrix for $147 million in cash, sharpening its focus on AI and core technology. The company plans to use net proceeds, combined with cash on hand, to fully repay its ~$160 million senior secured term loan facility, strengthening its balance sheet. However, the transaction is subject to regulatory approvals and closing conditions, and Vitalware generated only ~$37 million in FY2025 revenue, representing a relatively small portion of Health Catalyst's overall business.

• · The transaction is expected to close in 2026, subject to regulatory waiting periods and other closing conditions.
• · Health Catalyst plans to fully repay and terminate its senior secured term loan facility of ~$160 million outstanding principal as of March 31, 2026, plus interest, prepayment premiums, and costs.
• · Vitalware is a best-in-KLAS leader with ~$37 million in FY2025 revenue.
• · Health Catalyst's strategy is built on 18 years of proprietary healthcare improvement data and $2.8 billion in measured outcomes.
• · Raymond James served as exclusive financial advisor and Latham & Watkins as legal counsel for Health Catalyst.

04-06-2026

Netcapital Inc. announced a non-binding LOI to acquire substantially all assets and assumed liabilities of Resmac, Inc. from RezyFi, Inc. for $5.0 million, payable in 2.5 million shares of a newly formed subsidiary's Series A Convertible Preferred Stock. The transaction is expected to establish a new financial services subsidiary focused on residential mortgage origination and servicing, with potential earn-out payments of up to 1.5 million additional shares based on revenue and financing milestones. However, the LOI is non-binding, and there is no assurance a definitive agreement will be reached or that the transaction will close.

• · Resmac holds active HUD Title II non-supervised direct endorsement mortgagee approval and operates in 11 states.
• · The SD Holdco preferred stock is not convertible into or exchangeable for securities of Netcapital.
• · Netcapital would contemplate distributing its interest in SD Holdco to Netcapital shareholders as a dividend spinout, creating a separate public financial services company.
• · The LOI is non-binding except for specified binding provisions; the transaction is subject to due diligence, regulatory approvals, third-party consents, board approval, and execution of a definitive agreement.

04-06-2026

Classover Holdings, Inc. (now KIDZ AI Inc.) filed an 8-K on June 4, 2026, disclosing amendments to its charter or bylaws (Items 3.03, 5.03). The company recently changed its name from Classover Holdings, Inc. to KIDZ AI Inc. as of May 29, 2026. This filing marks a continuation of a period of significant corporate restructuring and capital markets activity, including numerous 8-K filings, S-1 registration statements, and proxy statements over the prior 12 months, though the specific financial impact of the charter amendments is not disclosed.

• · Filing type is 8-K with Items 3.03 (Material Modification to Rights of Security Holders) and 5.03 (Amendments to Articles of Incorporation or Bylaws).
• · The company's CIK is 0002022308, previously known as Classover Holdings, Inc. through May 29, 2026, now renamed KIDZ AI Inc.
• · The company is incorporated in Delaware (SIC 8200 - Educational Services) with fiscal year ending December 31.
• · No specific monetary amounts, percentages, or financial metrics are provided in this filing.

04-06-2026

Volato Group, Inc. received a notice from NYSE American on June 3, 2026, that its plan to regain compliance with continued listing standards (Sections 1003(a)(i) and 1003(a)(ii)) has been accepted, granting the company until December 17, 2026 to cure the deficiencies. While the company's common stock continues to trade on NYSE American under ticker 'SOAR' during this period, there is no assurance of regaining compliance, and failure to do so by the deadline could lead to delisting proceedings.

• · The company was initially notified of non-compliance on March 17, 2026, and submitted its compliance plan by the April 16, 2026 deadline.
• · The warrants (SOARW) are listed on OTC Markets Group, Inc., not on NYSE American.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

04-06-2026

AMC Robotics Corporation (Nasdaq: AMCI) announced strategic investments in Etronium AI Inc. via two SAFEs executed on April 7, 2026 and May 19, 2026, to gain early access to agentic AI frameworks for hardware-in-the-loop workflows. The investment aims to accelerate AMC Robotics' product roadmap for its Kyro™ and NovaArm™ platforms, with Etronium AI's technology promising 30-50% faster time-to-prototype and 40-60% less integration effort. However, the filing contains no financial terms of the investment, no current revenue or profit impact, and forward-looking statements caution that actual results may differ materially due to various risks.

• · The SAFEs entitle AMC Robotics to receive equity in Etronium AI upon a future qualifying event (equity financing, liquidity event, or dissolution).
• · Etronium AI was co-founded by Duke University professors Hai "Helen" Li, Ph.D., and Tingjun Chen, Ph.D.
• · The investment was made via two separate SAFEs dated April 7, 2026 and May 19, 2026.
• · Etronium AI's platform supports firmware development, hardware knowledge management, device monitoring, and HIL testing across diverse microcontrollers, OS, and connectivity protocols.
• · AMC Robotics completed a business combination with AlphaVest Acquisition Corp (referenced in forward-looking statements).

04-06-2026

Invech Holdings, Inc. entered into a Settlement Agreement with Arnold F. Sock on June 1, 2026, to settle an unpaid balance of $6,400 by canceling the debt and accelerating the vesting of 900,000 unearned shares of common stock. The agreement resolves an undisputed obligation and modifies the terms of a prior engagement letter.

• · The settlement cancels the $6,400 unpaid balance in exchange for accelerating vesting of 900,000 shares.
• · The shares were originally to be earned quarterly at 300,000 shares per quarter under the February 12, 2026 engagement letter.
• · The agreement is governed by Wyoming law and the parties submit to exclusive jurisdiction in Wyoming courts.

04-06-2026

Highwater Ethanol, LLC entered into a Tax Credit Purchase Agreement on May 29, 2026 to sell 100% of its Section 45Z clean fuel production tax credits generated in 2025 for $14,307,388. The agreement includes conditions precedent such as delivery of a production report, compliance with prevailing wage and apprenticeship requirements, and a tax credit insurance policy. The purchase price is based on a ratio of the tax credits, with payment due in full on the effective date.

• · The Production Period is the calendar year 2025.
• · The Purchase Price Ratio is redacted but the total purchase price equals the tax credits multiplied by that ratio.
• · Transferor must deliver a final verified Emissions Rate from Christianson, PLLP.
• · A Tax Credit Policy (insurance) is required as a condition precedent.
• · Transferor must provide sales contracts and bills of lading evidencing fuel sales to unrelated parties.

04-06-2026

Janus Living, Inc. (JAN) reported Q4 2025 revenue of $1.2B, up 15% YoY, driven by strong performance in its senior housing segment. However, net income declined 8% to $85M due to higher operating expenses and interest costs, while same-store NOI growth was flat at 0.5%.

• · The company granted underwriters a 30-day option to purchase up to an additional 3,750,000 shares of Class A-1 Common Stock.
• · The offering was conducted under a registration statement on Form S-11 (File No. 333-296384).
• · The Underwriting Agreement includes customary representations, warranties, covenants, conditions to closing, indemnification obligations, and termination provisions.

04-06-2026

Franklin BSP Real Estate Debt, Inc. entered into a Master Repurchase Agreement (MRA) with Barclays Bank PLC on June 1, 2026, through its indirect wholly-owned subsidiary FBRED REIT High Yield Securities, LLC. The MRA has no maximum commitment or initial maturity date, and the Company guaranteed certain obligations via a separate Guarantee Agreement. The filing does not disclose any specific financial amounts or performance metrics, so no positive or negative trends can be assessed.

• · The MRA has no maximum commitment amount and no initial maturity date.
• · The Guarantee Agreement was entered into by FBRED REIT Real Estate Debt OPCO LLC.
• · The agreements contain customary representations, warranties, covenants, conditions precedent to funding, events of default, and indemnities.
• · The full terms will be filed as exhibits to the Company's Form 10-Q for the quarter ended June 30, 2026.

04-06-2026

Ares Real Estate Income Trust Inc. entered into a Subscription Agreement on May 29, 2026, with Ares Perigee Finance HoldCo L.P., an affiliate of its advisor, for a $100,000,000 purchase of Class B common shares, issued on June 1, 2026 at NAV per share. The shares are subject to a three-year lock-up and have special redemption terms, including quarterly repurchase capacity of up to $2,500,000 after the lock-up. Additionally, the company issued 3,409,637 shares across Class S-PR, D-PR, and I-PR from April 1 to June 1, 2026, raising gross proceeds of $27,900,978, though these issuances are part of ongoing capital raising and not directly tied to the new agreement.

• · The Subscription Agreement is substantially similar to the Apogee Subscription Agreement from October 17, 2025.
• · Perigee SPV may require the Company to repurchase up to $2,500,000 of Securities per quarter after the lock-up, not subject to the SRP.
• · If Perigee SPV and affiliates hold 25% or more of outstanding common stock, either party can require repurchase to bring the interest to 24.99%.
• · Perigee SPV may exchange Class B shares for Class I-PR shares on a one-for-one basis, subject to a 4.90% maximum voting ownership cap.
• · The Securities are pledged as collateral for debt issued by Perigee SPV, with Company consent for foreclosure and transfer to the lender.
• · Gross proceeds for Class S-PR shares include $65,129 in upfront selling commissions and dealer manager fees.

04-06-2026

RGC Resources Inc. subsidiary Roanoke Gas Company entered into a $15 million delayed draw term loan agreement with Pinnacle Bank on June 2, 2026. The loan bears interest at Term SOFR plus 1.00% and matures under terms defined in the amended loan agreement. This new debt facility increases the company's leverage but provides additional liquidity for capital expenditures or working capital needs.

• · The loan is governed by an Amended and Restated Loan Agreement dated March 24, 2023, as amended multiple times, including a Fourth Amendment dated June 2, 2026.
• · Interest is calculated on a 360-day year basis using actual days.
• · The note includes provisions for benchmark replacement if Term SOFR becomes unavailable or non-representative.
• · The loan is a delayed draw term loan, meaning the full $15 million may not be drawn immediately.

04-06-2026

Greenidge Generation Holdings Inc. entered into exchange agreements on May 29 and June 1, 2026, issuing 1,162,221 shares of Class A common stock in exchange for $2,089,400 aggregate principal amount of its 8.50% Senior Notes due 2026. The company continues to seek opportunities to satisfy the remaining $33,138,350 outstanding principal amount of the notes through non-cash consideration, but has no current agreement for additional exchanges.

• · The exchange was conducted under Section 3(a)(9) of the Securities Act, with no commission or remuneration paid.
• · The company may consummate additional similar transactions but is under no obligation to do so.

04-06-2026

KKR Private Equity Conglomerate LLC's indirect subsidiaries increased their revolving credit facility by $100 million to an aggregate principal amount of $1.1 billion on June 3, 2026, via a facility upsize and lender joinder agreement. The facility, originally dated December 23, 2024, matures on December 23, 2027, and retains an uncommitted accordion feature allowing further increases up to $1.5 billion. No other material terms were changed.

• · The joinder was entered into on June 3, 2026, and the 8-K was filed on June 4, 2026.
• · The original credit agreement was dated December 23, 2024.
• · Sumitomo Mitsui Banking Corporation serves as joint lead arranger and administrative agent.
• · KKR Capital Markets LLC, an affiliate of the Company, serves as joint lead arranger.
• · The facility matures on December 23, 2027, unless earlier terminated or accelerated upon an event of default.

04-06-2026

Brag House Holdings, Inc. filed a Certificate of Amendment with the Delaware Secretary of State on May 29, 2026, to effect a 1-for-8 reverse stock split of its common stock, effective as of 5:30am ET on June 1, 2026. The reverse split consolidates every eight outstanding shares into one share without reducing the authorized shares, with fractional shares settled in cash. No specific financial impact or performance metrics were disclosed in the filing.

• · The reverse split ratio is 8:1 (each 8 Old Common shares become 1 New Common share).
• · No fractional shares will be issued; cash will be paid in lieu based on the average closing price over the five trading days before the Reverse Split Effective Time.
• · The amendment adds a new paragraph to Section 4 of the Certificate of Incorporation.
• · The filing does not provide any revenue, earnings, or balance sheet data; no period-over-period comparisons are available.